NASDAQ:ORIC

ORIC Pharmaceuticals (ORIC) Stock Forecast, Price & News

$5.84

-0.05 (-0.85%)

(As of 10:21 AM ET)

Compare

Today's Range: $5.64
▼
$5.91
50-Day Range: $5.89
▼
$9.28
52-Week Range: $2.36
▼
$9.79

Volume: 229,555 shs
Average Volume: 308,459 shs
Market Capitalization: $318.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

ORIC Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 154.7% Upside
$15.00 Price Target
Short Interest: Bearish
19.65% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.59
Upright™ Environmental Score
News Sentiment: 1.13
Based on 2 Articles This Week
Insider Trading: Selling Shares
$118,900 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.96) to ($2.02) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

454th out of 975 stocks

Pharmaceutical Preparations Industry

201st out of 455 stocks

3.5

Analyst's Opinion

Consensus Rating
ORIC Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, ORIC Pharmaceuticals has a forecasted upside of 154.7% from its current price of $5.89.
Amount of Analyst Coverage
ORIC Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
19.65% of the float of ORIC Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
ORIC Pharmaceuticals has a short interest ratio ("days to cover") of 18.1, which indicates bearish sentiment.
Change versus previous month
Short interest in ORIC Pharmaceuticals has recently increased by 2.13%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
ORIC Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ORIC Pharmaceuticals does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ORIC Pharmaceuticals has received a 77.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for ORIC Pharmaceuticals is -0.59.

4.0

News and Social Media Coverage

News Sentiment
ORIC Pharmaceuticals has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for ORIC Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
5 people have searched for ORIC on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
4 people have added ORIC Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ORIC Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $118,900.00 in company stock.
Percentage Held by Insiders
Only 5.34% of the stock of ORIC Pharmaceuticals is held by insiders.
Percentage Held by Institutions
91.30% of the stock of ORIC Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for ORIC Pharmaceuticals are expected to decrease in the coming year, from ($1.96) to ($2.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ORIC Pharmaceuticals is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ORIC Pharmaceuticals is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ORIC Pharmaceuticals has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ORIC Pharmaceuticals (NASDAQ:ORIC) Stock

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ORIC Price History

30 days | 90 days | 365 days | Advanced Chart

ORIC Stock News Headlines

September 26, 2023 | finance.yahoo.com

NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD

September 23, 2023 | americanbankingnews.com

ORIC Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated at Wedbush

October 3, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

September 20, 2023 | benzinga.com

ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference

September 20, 2023 | finance.yahoo.com

ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference

September 13, 2023 | msn.com

Navigating ORIC's Robust Strategy Against Cancer Drug Resistance

August 17, 2023 | markets.businessinsider.com

Oric Pharmaceuticals (ORIC) Receives a Buy from Robert W. Baird

August 16, 2023 | msn.com

Baird Maintains ORIC Pharmaceuticals (ORIC) Outperform Recommendation

October 3, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

August 15, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)

August 11, 2023 | msn.com

Markets Today: Stocks Fall on a Hot U.S. July PPI

August 11, 2023 | msn.com

ORIC Pharmaceuticals GAAP EPS of -$0.50 beats by $0.08

August 11, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

August 4, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 28, 2023 | markets.businessinsider.com

Why Oric Pharmaceuticals Stock Is Shooting Higher Today

June 26, 2023 | finance.yahoo.com

Why Shares of Oric Pharmaceuticals Jumped Monday

June 26, 2023 | seekingalpha.com

ORIC Pharmaceuticals launches ~$85M private placement of shares, warrants

June 26, 2023 | markets.businessinsider.com

ORIC Pharma Surges On $85 Mln Private Placement Financing

June 26, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Announces $85 Million Private Placement Financing

June 8, 2023 | msn.com

HC Wainwright & Co. Reiterates ORIC Pharmaceuticals (ORIC) Buy Recommendation

May 31, 2023 | finance.yahoo.com

ORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference

May 12, 2023 | msn.com

HC Wainwright & Co. Maintains ORIC Pharmaceuticals (ORIC) Buy Recommendation

May 8, 2023 | msn.com

ORIC Pharmaceuticals GAAP EPS of -$0.53

May 8, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

May 5, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

April 25, 2023 | finance.yahoo.com

ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference

April 18, 2023 | finance.yahoo.com

ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

See More Headlines

Receive ORIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORIC Company Calendar

Last Earnings: 8/10/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ORIC
CUSIP: N/A
CIK: 1796280
Web: www.oricpharma.com
Phone: 650-388-5600
Fax: N/A
Employees: 89
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.00
High Stock Price Forecast: $27.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +154.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.18)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-89,120,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -40.74%
Return on Assets: -36.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.46
Quick Ratio: 18.46

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.62 per share
Price / Book: 1.05

Miscellaneous

Outstanding Shares: 54,530,000
Free Float: 51,621,000
Market Cap: $321.18 million
Optionable: Not Optionable
Beta: 0.92

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Richard A. Heyman Ph.D. (Age 66)
Co-Founder, Independent Chairman & Member of Scientific Advisory Board
Comp: $93k

Dr. Jacob M. Chacko M.B.A. (Age 44)
M.D., Pres, CEO & Director
Comp: $921.32k

Mr. Dominic G. Piscitelli CPA (Age 48)
CPA, M.B.A., Chief Financial Officer
Comp: $636.91k

Dr. Pratik S. Multani M.D. (Age 56)
M.S., Chief Medical Officer
Comp: $686.88k

Dr. Charles L. Sawyers B.A. (Age 64)
BA, M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board

Dr. Scott W. Lowe Ph.D.
Co-Founder & Member of Scientific Advisory Board

Dr. Lori Sickels Friedman Ph.D. (Age 59)
Chief Scientific Officer

Dr. Christian V. Kuhlen Esq. (Age 50)
J.D., M.D., Gen. Counsel

Mr. Daniel Iazzetti
VP & Head of People

Dr. Edna Chow Maneval (Age 63)
Sr. VP of Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ORIC Stock - Frequently Asked Questions

Should I buy or sell ORIC Pharmaceuticals stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ORIC Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORIC shares.
View ORIC analyst ratings or view top-rated stocks.
What is ORIC Pharmaceuticals' stock price forecast for 2023?: 7 brokerages have issued 12 month price targets for ORIC Pharmaceuticals' shares. Their ORIC share price forecasts range from $8.00 to $27.00. On average, they anticipate the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 154.7% from the stock's current price.
View analysts price targets for ORIC or view top-rated stocks among Wall Street analysts.
How have ORIC shares performed in 2023?: ORIC Pharmaceuticals' stock was trading at $5.89 at the beginning of the year. Since then, ORIC stock has increased by 0.0% and is now trading at $5.89.
View the best growth stocks for 2023 here.
When is ORIC Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our ORIC earnings forecast.
How were ORIC Pharmaceuticals' earnings last quarter?: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its earnings results on Thursday, August, 10th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.08.
What other stocks do shareholders of ORIC Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE), DocuSign (DOCU), Vaxart (VXRT), Delta Air Lines (DAL) and Datadog (DDOG).

When did ORIC Pharmaceuticals IPO?: (ORIC) raised $75 million in an initial public offering (IPO) on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities acted as the underwriters for the IPO.
What is ORIC Pharmaceuticals' stock symbol?: ORIC Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORIC."
How do I buy shares of ORIC Pharmaceuticals?: Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ORIC Pharmaceuticals' stock price today?: One share of ORIC stock can currently be purchased for approximately $5.89.
How much money does ORIC Pharmaceuticals make?: ORIC Pharmaceuticals (NASDAQ:ORIC) has a market capitalization of $321.18 million. The company earns $-89,120,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis.
How can I contact ORIC Pharmaceuticals?: ORIC Pharmaceuticals' mailing address is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.oricpharma.com. The company can be reached via phone at 650-388-5600 or via email at investors@oricpharma.com.

This page (NASDAQ:ORIC) was last updated on 10/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial